Avadel Phrmctcls ADR (AVDL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Gregory J. Divis
Employees:
70
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN, IRELAND 15
636-449-1830

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Data derived from most recent annual or quarterly report
Market Cap 507.658 Million Shares Outstanding59.03 Million Avg 30-day Volume 930.214 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.56
Price to Revenue0.0 Debt to Equity-10.9512 EBITDA-93.009 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value329.328 Million
Current Ratio2.728 EPS Growth-1.065 Quick Ratio2.565
1 Yr BETA 1.5262 52-week High/Low 10.02 / 1.05 Profit Margin0.0
Operating Cash Flow Growth-4.7546 Altman Z-Score-5.8626 Free Cash Flow to Firm -26.429 Million
View SEC Filings from AVDL instead.

View recent insider trading info

Funds Holding AVDL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVDL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-18:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-04:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-25:
    Item 8.01: Other Events
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-05:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-07-22:
    Item 8.01: Other Events
  • 8-K: filed on 2022-07-19:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-29:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    25 Thousand total shares from 2 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MCHUGH THOMAS S CHIEF FINANCIAL OFFICER

    • Officer
    76,500 2022-11-29 2

    ENDE ERIC J

    • Director
    154,900 2022-11-22 4

    GLASS GEOFFREY MICHAEL

    • Director
    0 2022-08-05 4

    THORNTON PETER J.

    • Director
    42,000 2022-08-03 2

    MCCAMISH MARK ANTHONY

    • Director
    42,000 2022-08-03 1

    PALCZUK LINDA

    • Director
    42,000 2022-08-03 2

    DIVIS GREGORY J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    149,100 2022-05-27 1

    WILLIAMSON DOUGLAS J CHIEF MEDICAL OFFICER

    • Officer
    0 2022-02-14 2

    KIM RICHARD J CHIEF COMMERCIAL OFFICER

    • Officer
    137,500 2021-12-07 0

    HATTEN SANDRA L SEE REMARKS

    • Officer
    59,165 2019-12-12 0

    VAUGHN JASON SR. VP, TECHNICAL OPERATIONS

    • Officer
    0 2019-11-05 0

    KOTLER KEVIN

    BROADFIN CAPITAL, LLC

    BROADFIN HEALTHCARE MASTER FUND LTD

    • Director
    3,130,573 2019-08-07 0

    GUSKY DAVID P SEE REMARKS

    • Officer
    No longer subject to file 2019-06-30 0

    STAPLETON CRAIG R

    • Director
    No longer subject to file 2019-05-09 0

    DUBOW JORDAN CHIEF MEDICAL OFFICER

    • Officer
    0 2019-04-29 0

    KANAN MICHAEL F SEE REMARKS

    • Officer
    50,538 2019-03-07 0

    THOMPSON PHILLANDAS T. SEE REMARKS

    • Officer
    113,671 2019-03-07 0

    ANDERSON MICHAEL S SEE REMARKS

    • Officer
    • Director
    No longer subject to file 2018-12-28 0

    VAN ASSCHE BENOIT

    • SEE REMARKS
    No longer subject to file 2018-07-18 0

    FILDES FRANCIS

    • SEE REMARKS
    No longer subject to file 2018-07-18 0

    NAVARRE CHRISTOPHE

    • SEE REMARKS
    No longer subject to file 2018-07-18 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD PRIVATE DESIGN FUND II, L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT L.P.

    DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

    BREAKING STICK HOLDINGS, LLC

    • 10% Owner
    • *POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP
    No longer subject to file 2018-06-25 0

    D'SILVA DHIREN VP IRISH & EUROPEAN OPERATIONS

    • Officer
    No longer subject to file 2018-02-07 0

    MACKE SCOTT A.

    • SEE REMARKS
    No longer subject to file 2017-10-10 0

    DAVIS GREGORY J.

    • SEE REMARKS
    No longer subject to file 2017-10-10 0

    SULLIVAN STEPHEN G.

    • SEE REMARKS
    No longer subject to file 2017-10-10 0

    MONTEITH DAVID

    • SEE REMARKS
    No longer subject to file 2017-10-10 0

    ELROD MARCUS W

    • SEE REMARKS
    No longer subject to file 2017-10-10 0

    CERUTTI GUILLAUME

    • SEE REMARKS
    No longer subject to file 2017-06-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MCHUGH THOMAS S - Officer CHIEF FINANCIAL OFFICER

    2022-11-30 16:01:36 -0500 2022-11-29 P 5,000 $7.80 a 76,500 direct -7.2 -14.0 0.0 1 -16.5 4

    ENDE ERIC J - Director

    2022-11-23 16:01:31 -0500 2022-11-22 P 20,000 $7.80 a 154,900 direct -0.5006 16.1452 25.1564 5 -1.8773 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 20:15:04 UTC -3.0122 6.8322 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 19:45:04 UTC -3.0122 6.8322 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 19:15:04 UTC -3.0122 6.8322 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 18:45:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 18:15:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 17:45:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 17:15:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 16:45:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 16:15:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 15:45:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 15:15:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 14:45:04 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 14:15:03 UTC -2.9017 6.7217 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 13:45:03 UTC -1.1793 4.9993 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 13:15:03 UTC -1.1793 4.9993 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-09 12:45:03 UTC -1.1793 4.9993 350000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-08 22:15:03 UTC -1.1793 4.9993 250000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-08 21:45:04 UTC -1.1793 4.9993 250000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-08 21:15:03 UTC -1.1793 4.9993 250000
    AVADEL PHARMACEUTICALS-ADR AVDL 2022-12-08 20:45:04 UTC -0.9308 4.7508 250000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin
    Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund AVDL -67067.0 shares, $-445324.88 2022-08-31 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund AVDL -64759.0 shares, $-324442.59 2022-09-30 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio AVDL -41760.0 shares, $-209217.6 2022-09-30 N-PORT
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.59% 2022-12-07 GERMANY

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.58% 2022-07-19 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.66% 2022-07-27 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.58% 2022-08-12 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.65% 2022-09-22 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.94% 2018-06-01 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.81% 2018-06-05 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.57% 2018-06-08 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 1.34% 2018-06-26 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 0.99% 2018-08-22 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 0.63% 2018-08-30 GERMANY

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments